**Proteins** 

# **Screening Libraries**

# **Product** Data Sheet

## Genistein

Cat. No.: HY-14596 CAS No.: 446-72-0 Molecular Formula:  $C_{15}H_{10}O_{5}$ Molecular Weight: 270.24

Target: EGFR; Autophagy; Apoptosis; Endogenous Metabolite

Pathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Autophagy; Apoptosis; Metabolic

Enzyme/Protease

Storage: Powder -20°C 3 years

4°C 2 years

-80°C 1 year In solvent

> -20°C 6 months

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: ≥ 100 mg/mL (370.04 mM)

H<sub>2</sub>O: < 0.1 mg/mL (ultrasonic; warming; heat to 60°C) (insoluble)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.7004 mL	18.5021 mL	37.0041 mL
	5 mM	0.7401 mL	3.7004 mL	7.4008 mL
	10 mM	0.3700 mL	1.8502 mL	3.7004 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 50% PEG300 >> 50% saline Solubility: 5 mg/mL (18.50 mM); Suspended solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 3.75 mg/mL (13.88 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 3 mg/mL (11.10 mM); Clear solution
- 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 3 mg/mL (11.10 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

Description

Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.

IC <sub>50</sub> & Target	EGFR 0.6 μM (IC <sub>50</sub> , Cell Assay)
In Vitro	Genistein inhibits serum-stimulated growth of MCF-7 and T47D ER $^+$ cells with IC $_{50}$ values of 7.6 and 8.7 $\mu$ g/mL by dye exclusion, respectively, and 8.7 and 10.6 $\mu$ g/mL by [ $^3$ H]thymidmne incorporation, respectively. These values are similar to the IC $_{50}$ values of 9.4 and 7 $\mu$ g/mL for MCF-7 and T47D ER $^+$ cells, respectively, obtained with the MTT assay. Additionally, Genistein at concentrations up to 20 $\mu$ g/mL does not alter MTT mitochondrial reduction when compared to control cells in an 8 h incubation period. Furthermore, neither biochanin A or daidzein are found to interfere with the MTT assay at IC $_{50}$ concentrations. Therefore, the MTT assay is valid for determining growth inhibition by Genistein at concentrations under 20 $\mu$ g/mL in the systems studied [ $^{11}$ ].
In Vivo	Bisphenol A (BPA) treatment alone and combined with Genistein had no significant effect on the protein expression of LC3II and PPAR $\alpha$ in liver of STD- or HFD-fed rats (P>0.05; P>0.05). Significant decreasing of the protein expression of PPAR $\gamma$ in liver is observed when Genistein is added to rats, compared to either HFD group or HFD-BPA group <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **PROTOCOL**

### Cell Assay [1]

The IC $_{50}$  values for Genistein are determined by the MTT assay. Briefly, the MTT assay is a colorimetric assay that is based on the ability of living but not dead cells to reduce a tetrazolium-based compound to a blue formazan product. The formazan crystals are solubilized in DMSO, and the absorbance is measured at 540 nm. The absorbance at 540 nm is proportional to the number of viable cells. The IC $_{50}$  values obtained with the MTT assay are compared with the IC $_{50}$  values obtained by counting viable cells using trypan blue dye exclusion and by tritiated thymidine incorporation into DNA $^{[1]}$ . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

# Animal Administration [2][3]

### Mice<sup>[2]</sup>

Balb/c male mice are used. Genistein is administered as follows: On days 1-30, Genistein once daily, interaperitoneally injecting. Morphine plus Genistein is administered as follows: On days 1-30, Genistein once daily plus morphine, interaperitoneally injecting (17, 18). The same volume of saline is administered. Mice are randomly divided into 8 groups (n=6). 1) Normal saline group (1 mL DW/daily); 2) Morphine treated group; 3) Genistein 1 mg/kg treated group; 4) Genistein 2 mg/kg treated group; 5) Genistein 4 mg/kg treated group; 6) Morphine plus Genistein 1 mg/kg treated group; 7) Morphine plus Genistein 2 mg/kg treated group; 8) Morphine plus Genistein 4 mg/kg treated group. Rats<sup>[3]</sup>

Male 8-week-old Wistar rats (150-180g) are used. After one week acclimation, all rats are randomly divided into 8 groups with 10 rats per group and treated for 35 weeks as follows: (1) STD group is fed with rodent standard chow diet (STD); (2) STD-BPA group is fed with STD and administered with BPA (50  $\mu$ g/kg/day); (3) STD-(BPA+G) group is fed with STD and administered with BPA (50  $\mu$ g/kg/day) plus Genistein (10 mg/kg/day); (4) STD-G group is fed with STD and administered with Genistein (10 mg/kg/day); (5) HFD group received high-fat diet (HFD); (6) HFD-BPA group is fed with HFD and administered with BPA (50  $\mu$ g/kg/day); (7) STD-(BPA+G) group is fed with HFD and administered with BPA (50  $\mu$ g/kg/day) plus Genistein (10 mg/kg/day); (8) HFD-G group is fed with HFD and administrated with Genistein (10 mg/kg/day). All the male genitors are treated for 35 weeks consecutively. The details of BPA (50  $\mu$ g/kg/day) and Genistein (10 mg/kg/day) treatment methods have been described previously: BPA is dissolved in corn oil and diluted with three stock solutions (20, 40, 80, and 120  $\mu$ g/mL).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **CUSTOMER VALIDATION**

• Nat Nanotechnol. 2020 Dec;15(12):1043-1052.

- Bioact Mater. 6 (2021) 2158-2172.
- ACS Nano. 2020 Apr 28;14(4):4890-4904.
- Adv Sci (Weinh). 2023 Apr 24;e2207017.
- Small. 2020 Nov;16(44):e2004172.

See more customer validations on  $\underline{www.MedChemExpress.com}$ 

### **REFERENCES**

[1]. Peterson G, et al. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ. 1996 Oct;7(10):1345-51.

[2]. Ding S, et al. Environmentally Relevant Dose of Bisphenol A Does Not Affect Lipid Metabolism and Has No Synergetic or Antagonistic Effects on Genistein's Beneficial Roles on Lipid Metabolism. PLoS One. 2016 May 12;11(5):e0155352.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA